

# Genmab – QuickView

9 January 2013

## Investment summary: Stars are realigning

Genmab's daratumumab has the potential to be a game changer. Activity of the anti-CD38 antibody in myeloma represents a new and complementary mechanism of action, meeting a major unmet medical need. Heavily pre-treated multiple myeloma patients extraordinarily achieved a partial response after short single-agent exposure. Although early stage, the data is sufficiently impressive for J&J and Genmab to communicate an ambitious clinical trial programme this year across a variety of haematological cancers, targeting a market opportunity of c \$9bn.

### Limited toxicity easily managed with steroids

In a dose-escalating Phase I/II study, the safety and toxicity of daratumumab (a fully human IgG anti-CD38 monoclonal antibody) were assessed in 32 patients with relapsed and relapsed-refractory multiple myeloma (MM). Daratumumab monotherapy in patients already exposed to two to 11 therapies caused limited toxicity easily managed with steroids. The most common adverse events were infusion-related reactions. It is particularly impressive, the study met its primary safety end point, given the widespread expression of CD38 in normal human tissue.

### Extraordinary efficacy signal with single-agent exposure

At the higher doses (4-24mg/kg), daratumumab induced a dose-related reduction in the M-component, paraprotein, a marker of disease activity. A disappearance of tumour cells from bone marrow samples was also detected. Moreover, at doses of  $\geq 4$ mg/kg, a third of patients achieved a partial response and two-thirds achieved at least a minor response. This is an exceptional finding after short single-agent exposure and has never been seen before with a monoclonal antibody. Data on extended exposure (up to 24 months) and combined with Revlimid are expected from 2014.

### Massive market potential

Genmab estimates the MM market at \$3.9bn pa. Daratumumab was partnered with Janssen Biotech (a subsidiary of J&J) in August 2012 in a deal worth up to \$1.1bn. This includes potential development in six disclosed haematological cancers, for which the companies estimate a total market potential (including MM) of \$9bn pa.

### Valuation: Daratumumab springboard

As well as exciting daratumumab data, albeit early stage, the \$55m upfront received from J&J via its out-licensing and an equity investment of \$80m, has extended the cash runway to beyond 2016e, sufficient to see Phase III data read-outs of ofatumumab, which, if positive, would significantly expand its label and allow Genmab to develop certain of its antibody-drug conjugates alone to retain more value for shareholders.


#### Consensus estimates

| Year end | Revenue (DKKm) | PBT (DKKm) | EPS (DKK) | Net cash (DKKm) | P/E (x) | Yield (%) |
|----------|----------------|------------|-----------|-----------------|---------|-----------|
| 12/10    | 582            | (122)      | (3.19)    | 1,516           | N/A     | N/A       |
| 12/11    | 351            | (210)      | (7.57)    | 1,089           | N/A     | N/A       |
| 12/12e   | 450            | (126)      | (4.37)    | 1,319           | N/A     | N/A       |
| 12/13e   | 587            | (38)       | (0.60)    | 1,069           | N/A     | N/A       |

Source: Bloomberg

Price DKK80.5  
Market cap DKK4,049m

#### Share price graph



#### Share details

Code GEN  
Listing Copenhagen  
Sector Biotechnology  
Shares in issue 50.3m

#### Business

Genmab is a Danish biotech focused on human antibody therapeutics for treating cancers. It has one marketed product partnered with GSK, Arzerra (ofatumumab), for the treatment of CLL. There are also three products in clinical development and >12 PC candidates. It has cash to last beyond 2016e, sufficient to see the read-out of its Phase III ofatumumab studies.

#### Bull

- Read-out of five Phase III ofatumumab studies in 2013 and 2014.
- Roll-out of daratumumab clinical trial programme in 2013 as part of J&J \$1.1bn licensing deal.
- Clinical progress of antibody-drug conjugate platform and expansion of DuoBody & HexaBody collaborations.

#### Bear

- Ofatumumab is competing against Rituxan with c \$7bn in 2011 sales.
- Risk of clinical failure of daratumumab extension and combination studies.
- Cash burn associated with keeping its Minnesota production facility open.

#### Analysts

Luke Poloniecki +44 (0)20 3077 5700  
Robin Davison +44 (0)20 3077 5737

[healthcare@edisoninvestmentresearch.co.uk](mailto:healthcare@edisoninvestmentresearch.co.uk)

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

#### EDISON INVESTMENT RESEARCH LIMITED

Edison Investment Research Limited (Edison) is a leading international investment research company. Edison and its subsidiaries (Edison Group) have won industry recognition, with awards both in Europe and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison's research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York, Sydney and Wellington. Edison is authorised and regulated by the United Kingdom's Financial Services Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only.

#### DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). It is not intended for retail clients. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct an investment business and, accordingly, does not hold any positions in the securities mentioned in this report. However, their respective directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

Registered in England, number 4794244, Edison Investment Research Limited is authorised and regulated by the United Kingdom Financial Services Authority.

[www.edisoninvestmentresearch.co.uk](http://www.edisoninvestmentresearch.co.uk). Registered on the New Zealand Financial Service Providers Register, number 247505, Edison Investment Research (NZ) Limited is registered to provide wholesale and/or generic financial adviser services and is regulated by the New Zealand Financial Markets Authority.

**London** +44 (0)20 3077 5700  
Lincoln House, 296-302 High Holborn  
London, WC1V 7JH, UK

**New York** +1 646 653 7026  
245 Park Avenue, 24th Floor  
NY 10167, New York, US

**Wellington** + 64 4894 8555  
Level 15 HP Tower, 171 Featherston St  
Wellington 6011, NZ

**Sydney** +61 (0)2 9258 1162  
Level 33, Australia Square, 264 George St,  
Sydney, NSW 2000, Australia